Meta's ad standards prohibit five supplement claim classes. These are health claims, personal attributes, before-after imagery, testimonial claims, and misleading efficacy claims. Meta reviews both ad copy and landing page for these. In our observation, resubmits that address the cited class are more likely to clear.
Your supplement ad just got rejected. That is common in this vertical, and it does not mean the account is at risk yet. Meta rejects individual ads on specific claim classes long before it moves against the account itself. The fix is narrower than the help docs suggest: Meta evaluates which class of claim the ad copy fired, not whether the supplement itself is legal.
Here is the pattern Meta is watching, and the three concepts that separate a resubmit that clears from a rejection cascade.
In our observation, Meta rejects supplement ads on the ad copy and landing page, not on the product itself. FDA rules and ingredient safety are regulatory questions. Meta's ad review is a policy question. Meta reviews the ad and landing page for specific prohibited claim types.
Ads Manager shows a generic label. It might say Prohibited Content or Health Claims. The Graph API shows the specific class that fired and the phrase that triggered it. ComplyAi refers to this API-level view as the Enforcement Signal Layer. Resubmits anchored to the specific class clear review more consistently than resubmits anchored to the general category.
Meta's ad standards prohibit specific supplement claim types. Health claims cover weight loss, sleep, immune, and energy language. Personal attributes flag copy that implies the reader has a condition. Before-and-after imagery is banned across health and beauty. Testimonial claims fire when a customer quote carries a health outcome. Misleading efficacy claims fire on numeric outcomes tied to time windows (like lose 20 lbs in 30 days). Each fires on its own. Any one of them rejects the ad.
In our observation, supplement rejections resolve in one of two ways. Resubmits that address the cited claim class, with fixes on both the ad and the landing page, are significantly more likely to clear. Rejections that stack are more likely to escalate to a Stage 02 restriction.
Meta groups supplement rejections into a small set of prohibited claim classes. Health claims. Personal attributes. Before-after imagery. Testimonial claims with efficacy. Misleading efficacy claims. Meta cites one or more on every rejection. In our observation, rewrites that miss the cited class rarely clear.
Meta reviews two surfaces on a resubmit: the ad copy and the landing page. A clean ad pointing at a landing page with the same claim language re-triggers the rejection. Rewrites that fix only the ad correlate with re-rejection.
In our observation, rejections compound on the account. Multiple rejections in a short window can escalate to a Stage 02 restriction. Resubmits that address the pattern the first time correlate with faster clearance. Repeat variants without diagnosing the pattern correlate with cascade.
ComplyAi diagnoses the cited claim class. We rewrite both surfaces. We monitor the cadence on every supplement resubmit.
Below are three example categories. Each contrasts a pattern commonly flagged in review with one more often seen in successful reviews.
In our observation, resubmits that address the cited claim class on both surfaces clear review more consistently than appeals of the same class. Well-anchored appeals still overturn 30 to 35 percent of the time (ComplyAi Intelligence Graph, Q2 2026).
Most account-level restrictions begin as accumulated ad-level rejections. In our observation, five patterns are consistently associated with rejections that cascade beyond a single ad.
Multiple variants often re-trigger the same claim class.
Why: In our observation, variant volume without diagnosis compounds the rejection trendline and accelerates the path to a Stage 02 restriction.
Appeals on auto-reject class claims rarely reverse.
Why: In our observation, appeals route the ad into a longer review queue than a resubmit. Appeals resolve more consistently when the cited claim class is defensible with evidence.
Meta reviews the ad copy and landing page as one surface.
Why: In our observation, ad-only fixes with unchanged landing pages commonly re-trigger the same claim class at the destination read.
Testimonials with health outcomes fire the Testimonial claim class.
Why: In our observation, moving the claim from ad headline to a customer quote shifts which class fires but does not clear the underlying signal.
Rejections clustering on the same class over a short window correlate with account-level risk.
Why: In our observation, a rising rejection trendline precedes a Stage 02 restriction. A flat trendline with occasional rejections does not.